The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes
Open Access
- 23 March 2010
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (6) , 1269-1274
Abstract
OBJECTIVE: Continuous glucose monitoring (CGM) has been found to improve glucose control in type 1 diabetic patients. We estimated the cost-effectiveness of CGM versus standard glucose monitoring in type 1 diabetes. RESEARCH DESIGN AND METHODS: This societal cost-effectiveness analysis (CEA) was conducted in trial populations in which CGM has produced a significant glycemic benefit (A1C ≥7.0% in a cohort of adults aged ≥25 years and A1C <7.0% in a cohort of all ages). Trial data were integrated into a simulation model of type 1 diabetes complications. The main outcome was the cost per quality-adjusted life-year (QALY) gained. RESULTS: During the trials, CGM patients experienced an immediate quality-of-life benefit (A1C ≥7.0% cohort: 0.70 quality-adjusted life-weeks [QALWs], P = 0.49; A1C <7.0% cohort: 1.39 QALWs, P = 0.04) and improved glucose control. In the long-term, CEA for the A1C ≥7.0% cohort, CGM was projected to reduce the lifetime probability of microvascular complications; the average gain in QALYs was 0.60. The incremental cost-effectiveness ratio (ICER) was $98,679/QALY (95% CI −60,000 [fourth quadrant] to −87,000 [second quadrant]). For the A1C <7.0% cohort, the average gain in QALYs was 1.11. The ICER was $78,943/QALY (15,000 [first quadrant] to −291,000 [second quadrant]). If the benefit of CGM had been limited to the long-term effects of improved glucose control, the ICER would exceed $700,000/QALY. If test strip use had been two per day with CGM long term the ICER for CGM would improve significantly. CONCLUSIONS: Long-term projections indicate that CGM is cost-effective among type 1 diabetic patients at the $100,000/QALY threshold, although considerable uncertainty surrounds these estimates.Keywords
This publication has 24 references indexed in Scilit:
- Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years' DurationArchives of internal medicine (1960), 2009
- The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 DiabetesDiabetes Care, 2009
- Continuous Glucose Monitoring and Intensive Treatment of Type 1 DiabetesNew England Journal of Medicine, 2008
- What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?Medical Care, 2008
- Deficiencies of Cardiovascular Risk Prediction Models for Type 1 DiabetesDiabetes Care, 2006
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesNew England Journal of Medicine, 2005
- ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELSJournal of Biopharmaceutical Statistics, 2001
- Effect of Future Costs on Cost-Effectiveness of Medical Interventions Among Young AdultsMedical Care, 2000
- Lifetime Benefits and Costs of Intensive Therapy as Practiced in the Diabetes Control and Complications TrialJAMA, 1996
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993